Neuren Pharmaceuticals Ltd (NEU) - Net Assets

Latest as of June 2025: AU$323.27 Million AUD ≈ $228.74 Million USD

Based on the latest financial reports, Neuren Pharmaceuticals Ltd (NEU) has net assets worth AU$323.27 Million AUD (≈ $228.74 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$331.25 Million ≈ $234.38 Million USD) and total liabilities (AU$7.98 Million ≈ $5.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Neuren Pharmaceuticals Ltd to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets AU$323.27 Million
% of Total Assets 97.59%
Annual Growth Rate N/A
5-Year Change 1403.74%
10-Year Change 2426.76%
Growth Volatility 246.03

Neuren Pharmaceuticals Ltd - Net Assets Trend (2000–2024)

This chart illustrates how Neuren Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore Neuren Pharmaceuticals Ltd (NEU) total assets for the complete picture of this company's asset base.

Annual Net Assets for Neuren Pharmaceuticals Ltd (2000–2024)

The table below shows the annual net assets of Neuren Pharmaceuticals Ltd from 2000 to 2024. For live valuation and market cap data, see NEU stock market capitalisation.

Year Net Assets Change
2024-12-31 AU$363.90 Million
≈ $257.49 Million		 +77.34%
2023-12-31 AU$205.21 Million
≈ $145.20 Million		 +393.42%
2022-12-31 AU$41.59 Million
≈ $29.43 Million		 +5.95%
2021-12-31 AU$39.25 Million
≈ $27.77 Million		 +62.20%
2020-12-31 AU$24.20 Million
≈ $17.12 Million		 +74.77%
2019-12-31 AU$13.85 Million
≈ $9.80 Million		 -43.87%
2018-12-31 AU$24.67 Million
≈ $17.45 Million		 +50.75%
2017-12-31 AU$16.36 Million
≈ $11.58 Million		 +291.20%
2016-12-31 AU$4.18 Million
≈ $2.96 Million		 -70.96%
2015-12-31 AU$14.40 Million
≈ $10.19 Million		 -24.51%
2014-12-31 AU$19.08 Million
≈ $13.50 Million		 -21.67%
2013-12-31 AU$24.36 Million
≈ $17.23 Million		 +284.13%
2012-12-31 AU$6.34 Million
≈ $4.49 Million		 -32.93%
2011-12-31 AU$9.45 Million
≈ $6.69 Million		 +167.52%
2010-12-31 AU$3.53 Million
≈ $2.50 Million		 -51.91%
2009-12-31 AU$7.35 Million
≈ $5.20 Million		 +31.86%
2008-12-31 AU$5.57 Million
≈ $3.94 Million		 -26.20%
2007-12-31 AU$7.55 Million
≈ $5.34 Million		 -53.24%
2006-12-31 AU$16.15 Million
≈ $11.42 Million		 -49.79%
2005-12-31 AU$32.16 Million
≈ $22.75 Million		 +266.86%
2004-12-31 AU$8.77 Million
≈ $6.20 Million		 +159.56%
2003-12-31 AU$-14.72 Million
≈ $-10.41 Million		 -907.30%
2002-12-31 AU$1.82 Million
≈ $1.29 Million		 +115.67%
2001-12-31 AU$-11.63 Million
≈ $-8.23 Million		 -283.64%
2000-12-31 AU$-3.03 Million
≈ $-2.15 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Neuren Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 18043100000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings AU$180.43 Million 49.58%
Common Stock AU$165.27 Million 45.42%
Other Comprehensive Income AU$18.20 Million 5.00%
Total Equity AU$363.90 Million 100.00%

Neuren Pharmaceuticals Ltd Competitors by Market Cap

The table below lists competitors of Neuren Pharmaceuticals Ltd ranked by their market capitalization.

Company Market Cap
Wah Lee Industrial Corp
TW:3010
 $1.12 Billion
Hubei Tech Semiconductors Co
SHE:300046
 $1.12 Billion
Wavestone S.A.
PA:WAVE
 $1.12 Billion
Fujian Longxi Bearing Group Co Ltd
SHG:600592
 $1.12 Billion
Fujian Boss Software Development Co Ltd
SHE:300525
 $1.12 Billion
Chengdu Zhimingda Electronics Co. Ltd. A
SHG:688636
 $1.12 Billion
Jiangxi Firstar Panel Technology Co Ltd
SHE:300256
 $1.12 Billion
BIRLASOFT LIMITED
NSE:BSOFT
 $1.12 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Neuren Pharmaceuticals Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 205,207,000 to 363,904,000, a change of 158,697,000 (77.3%).
  • Net income of 142,043,000 contributed positively to equity growth.
  • Share repurchases of 10,426,000 reduced equity.
  • New share issuances of 1,660,000 increased equity.
  • Other comprehensive income increased equity by 24,511,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income AU$142.04 Million +39.03%
Share Repurchases AU$10.43 Million -2.87%
Share Issuances AU$1.66 Million +0.46%
Other Comprehensive Income AU$24.51 Million +6.74%
Other Changes AU$909.00K +0.25%
Total Change AU$- 77.34%

Book Value vs Market Value Analysis

This analysis compares Neuren Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.47x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 84.13x to 4.47x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2002-12-31 AU$0.15 AU$12.45 x
2004-12-31 AU$0.71 AU$12.45 x
2005-12-31 AU$1.61 AU$12.45 x
2006-12-31 AU$1.31 AU$12.45 x
2007-12-31 AU$0.61 AU$12.45 x
2008-12-31 AU$0.45 AU$12.45 x
2009-12-31 AU$0.50 AU$12.45 x
2010-12-31 AU$0.17 AU$12.45 x
2011-12-31 AU$0.25 AU$12.45 x
2012-12-31 AU$0.11 AU$12.45 x
2013-12-31 AU$0.39 AU$12.45 x
2014-12-31 AU$0.25 AU$12.45 x
2015-12-31 AU$0.17 AU$12.45 x
2016-12-31 AU$0.99 AU$12.45 x
2017-12-31 AU$0.18 AU$12.45 x
2018-12-31 AU$0.25 AU$12.45 x
2019-12-31 AU$0.14 AU$12.45 x
2020-12-31 AU$0.23 AU$12.45 x
2021-12-31 AU$0.33 AU$12.45 x
2022-12-31 AU$0.32 AU$12.45 x
2023-12-31 AU$1.57 AU$12.45 x
2024-12-31 AU$2.78 AU$12.45 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Neuren Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 39.03%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 66.61%
  • • Asset Turnover: 0.52x
  • • Equity Multiplier: 1.13x
  • Recent ROE (39.03%) is above the historical average (-73.93%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2002 -299.40% -257.29% 0.64x 1.83x AU$-5.64 Million
2004 -65.18% -406.79% 0.11x 1.48x AU$-6.57 Million
2005 -41.78% -1933.70% 0.01x 1.77x AU$-10.30 Million
2006 -62.65% -5848.46% 0.01x 1.21x AU$-11.73 Million
2007 -160.95% -1287.13% 0.06x 1.93x AU$-12.91 Million
2008 -276.70% -677.97% 0.27x 1.53x AU$-15.98 Million
2009 1.33% 1.99% 0.49x 1.37x AU$-649.43K
2010 -136.92% -105.28% 0.81x 1.60x AU$-5.25 Million
2011 -48.96% -112.06% 0.37x 1.17x AU$-5.60 Million
2012 -78.56% -95.51% 0.63x 1.31x AU$-5.74 Million
2013 -46.01% -235.69% 0.18x 1.08x AU$-13.75 Million
2014 -42.99% -283.08% 0.13x 1.15x AU$-10.23 Million
2015 -93.02% -800.78% 0.10x 1.17x AU$-14.84 Million
2016 -287.21% -381.40% 0.51x 1.48x AU$-12.43 Million
2017 20.09% 521.08% 0.04x 1.10x AU$1.65 Million
2018 12.46% 21.97% 0.53x 1.08x AU$606.10K
2019 -78.11% -2185.05% 0.03x 1.04x AU$-12.20 Million
2020 -37.99% -1282.15% 0.03x 1.03x AU$-11.61 Million
2021 -19.86% -243.79% 0.08x 1.02x AU$-11.72 Million
2022 0.44% 1.26% 0.34x 1.04x AU$-3.97 Million
2023 76.55% 67.73% 0.94x 1.21x AU$136.56 Million
2024 39.03% 66.61% 0.52x 1.13x AU$105.65 Million

Industry Comparison

This section compares Neuren Pharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $9,810,720
  • Average return on equity (ROE) among peers: -71.07%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Neuren Pharmaceuticals Ltd (NEU) AU$323.27 Million -299.40% 0.02x $1.12 Billion
Adalta Ltd (1AD) $3.70 Million -162.25% 0.87x $6.50 Million
Algorae Pharmaceuticals Ltd (1AI) $-1.33 Million 0.00% 0.00x $20.04 Million
ACRUX Ltd (ACR) $12.85 Million -73.71% 0.44x $3.20 Million
Actinogen Medical Ltd (ACW) $21.74 Million -43.69% 0.07x $105.70 Million
Argenica Therapeutics Ltd (AGN) $13.95 Million -39.28% 0.17x $15.45 Million
Arovella Therapeutics Ltd (ALA) $11.03 Million -40.87% 0.23x $58.08 Million
Anatara Lifesciences Ltd (ANR) $924.54K -218.83% 0.54x $1.57 Million
Alterity Therapeutics Ltd (ATH) $20.73 Million -6.40% 0.01x $76.95 Million
Amplia Therapeutics Ltd (ATX) $11.23 Million -30.16% 0.02x $50.82 Million
Avecho Biotechnology Ltd (AVE) $3.27 Million -95.48% 0.53x $28.59 Million

About Neuren Pharmaceuticals Ltd

AU:NEU Australia Biotechnology
Market Cap
$1.13 Billion
AU$1.60 Billion AUD
Market Cap Rank
#8597 Global
#209 in Australia
Share Price
AU$12.60
Change (1 day)
+1.04%
52-Week Range
AU$11.28 - AU$21.98
All Time High
AU$25.11
Categories
Companies in Australia Biotechnology
About

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 cl… Read more